Cargando…
Principles of Clinical Pharmacology /
Principles of Clinical Pharmacology is a successful survey covering the pharmacologic principles underlying the individualization of patient therapy and contemporary drug development. This essential reference continues to focus on the basics of clinical pharmacology for the development, evaluation,...
| Clasificación: | Libro Electrónico |
|---|---|
| Autor principal: | |
| Otros Autores: | , , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
San Diego :
Elsevier Science,
2012.
|
| Edición: | 3rd ed. |
| Temas: | |
| Acceso en línea: | Texto completo |
MARC
| LEADER | 00000cam a2200000Mi 4500 | ||
|---|---|---|---|
| 001 | EBOOKCENTRAL_ocn818109382 | ||
| 003 | OCoLC | ||
| 005 | 20240329122006.0 | ||
| 006 | m o d | ||
| 007 | cr |n|---||||| | ||
| 008 | 121101s2012 cau o 000 0 eng d | ||
| 010 | |a 2013371585 | ||
| 040 | |a MHW |b eng |e pn |c MHW |d YDXCP |d TEF |d OCLCQ |d EBLCP |d OCLCA |d UKDOC |d OCLCQ |d LVT |d OCLCO |d MERUC |d OCLCO |d OCLCQ |d OCLCO |d ZCU |d OCLCO |d U3W |d OCLCO |d OCLCA |d OCLCF |d OCLCO |d ICG |d AU@ |d OCLCO |d OCLCQ |d WYU |d OCLCO |d OCLCA |d VT2 |d DKC |d OCLCQ |d OCLCO |d OCLCQ |d OCLCO |d OCLCL | ||
| 019 | |a 1066533673 |a 1081217357 |a 1228589623 | ||
| 020 | |a 9780123854728 | ||
| 020 | |a 0123854725 | ||
| 020 | |z 9780123854711 (hardback) | ||
| 020 | |a 0123854717 | ||
| 020 | |a 9780123854711 | ||
| 029 | 1 | |a AU@ |b 000055852907 | |
| 029 | 1 | |a DEBBG |b BV044049827 | |
| 029 | 1 | |a GBVCP |b 737262680 | |
| 035 | |a (OCoLC)818109382 |z (OCoLC)1066533673 |z (OCoLC)1081217357 |z (OCoLC)1228589623 | ||
| 050 | 4 | |a RM301.28 |b .A84 2012 | |
| 060 | 4 | |a QV 38 |b A876p 2012 | |
| 082 | 0 | 4 | |a 615.1 |a 615.58 |
| 049 | |a UAMI | ||
| 100 | 1 | |a Atkinson, Arthur J., |c Jr. | |
| 245 | 1 | 0 | |a Principles of Clinical Pharmacology / |c Arthur J. Atkinson, Jr. [and others]. |
| 250 | |a 3rd ed. | ||
| 260 | |a San Diego : |b Elsevier Science, |c 2012. | ||
| 300 | |a 1 online resource (649 pages) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 588 | 0 | |a Print version record. | |
| 520 | |a Principles of Clinical Pharmacology is a successful survey covering the pharmacologic principles underlying the individualization of patient therapy and contemporary drug development. This essential reference continues to focus on the basics of clinical pharmacology for the development, evaluation, and clinical use of pharmaceutical products while also addressing the most recent advances in the field. Written by leading experts in academia, industry, clinical and regulatory settings, the third edition has been thoroughly updated to provide readers with an ideal reference covering the wide ran. | ||
| 505 | 0 | |a Front Cover -- Principles of Clinical Pharmacology -- Copyright -- Contents -- Preface to the First Edition -- Contributors -- Chapter 1 -- Introduction to Clinical Pharmacology -- BACKGROUND -- PHARMACOKINETICS -- REFERENCES -- PART I -- PHARMACOKINETICS -- Chapter 2 -- Clinical Pharmacokinetics -- THE TARGET CONCENTRATION STRATEGY -- CONCEPTS UNDERLYING CLINICAL PHARMACOKINETICS -- MATHEMATICAL BASIS OF CLINICAL PHARMACOKINETICS -- REFERENCES -- STUDY PROBLEMS -- Chapter 3 -- Compartmental Analysis of Drug Distribution -- FIT-FOR-PURPOSE MODELING OF DRUG DISTRIBUTION -- PHYSIOLOGICAL SIGNIFICANCE OF DRUG DISTRIBUTION VOLUMES -- PHYSIOLOGICAL BASIS OF MULTICOMPARTMENTAL MODELS OF DRUG DISTRIBUTION -- CLINICAL CONSEQUENCES OF DIFFERENT DRUG DISTRIBUTION PATTERNS -- ESTIMATING MODEL PARAMETERS FROM EXPERIMENTAL DATA -- REFERENCES -- STUDY PROBLEMS -- COMPUTER-BASED TUTORIALS -- Chapter 4 -- Drug Absorption and Bioavailability -- DRUG ABSORPTION -- BIOAVAILABILITY -- KINETICS OF DRUG ABSORPTION AFTER ORAL ADMINISTRATION -- REFERENCES -- STUDY PROBLEMS -- COMPUTER-BASED TUTORIALS -- Chapter 5 -- Effect of Renal Disease on Pharmacokinetics -- DRUG DOSING IN PATIENTS WITH IMPAIRED RENAL FUNCTION -- EFFECTS OF RENAL DISEASE ON RENAL DRUG EXCRETION MECHANISMS -- EFFECTS OF IMPAIRED RENAL FUNCTION ON NON-RENAL METABOLISM -- EFFECTS OF RENAL DISEASE ON DRUG DISTRIBUTION -- EFFECTS OF RENAL DISEASE ON DRUG ABSORPTION -- REFERENCES -- STUDY PROBLEM -- Chapter 6 -- Pharmacokinetics in Patients Requiring Renal Replacement Therapy -- KINETICS OF INTERMITTENT HEMODIALYSIS -- KINETICS OF CONTINUOUS AND SUSTAINED RENAL REPLACEMENT THERAPY -- CLINICAL CONSIDERATIONS -- REFERENCES -- COMPUTER-BASED TUTORIAL -- Chapter 7 -- Effect of Liver Disease on Pharmacokinetics -- HEPATIC ELIMINATION OF DRUGS -- EFFECTS OF LIVER DISEASE ON PHARMACOKINETICS. | |
| 505 | 8 | |a USE OF THERAPEUTIC DRUGS IN PATIENTS WITH LIVER DISEASE -- REFERENCES -- Chapter 8 -- Non-Compartmental and Compartmental Approaches to Pharmacokinetic Data Analysis -- INTRODUCTION -- KINETICS, PHARMACOKINETICS AND PHARMACOKINETIC PARAMETERS -- NON-COMPARTMENTAL ANALYSIS -- COMPARTMENTAL ANALYSIS -- NON-COMPARTMENTAL VS COMPARTMENTAL MODELS -- CONCLUSION -- REFERENCES -- Chapter 9 -- Distributed Models of Drug Kinetics -- INTRODUCTION -- CENTRAL ISSUES -- DRUG MODALITY I: DELIVERY ACROSS A PLANAR-TISSUE INTERFACE -- DRUG MODALITY II: DELIVERY FROM A POINT SOURCE, DIRECT INTERSTITIAL INFUSION -- SUMMARY -- REFERENCES -- Chapter 10 -- Population Pharmacokinetics -- INTRODUCTION -- ANALYSIS OF PHARMACOKINETIC DATA -- POPULATION PHARMACOKINETICS -- MODEL APPLICATIONS -- CONCLUSIONS -- REFERENCES -- PART II -- DRUG METABOLISM AND TRANSPORT -- Chapter 11 -- Pathways of Drug Metabolism -- INTRODUCTION -- PHASE I BIOTRANSFORMATIONS -- PHASE II BIOTRANSFORMATIONS (CONJUGATIONS) -- ADDITIONAL EFFECTS ON DRUG METABOLISM -- REFERENCES -- Chapter 12 -- Methods of Analysis of Drugs and Drug Metabolites -- INTRODUCTION -- CHOICE OF ANALYTICAL METHODOLOGY -- PRINCIPLES OF ANALYSIS -- EXAMPLES OF CURRENT ASSAY METHODS -- ASSAY SELECTION -- REFERENCES -- Chapter 13 -- Clinical Pharmacogenetics -- INTRODUCTION -- HIERARCHY OF PHARMACOGENETIC INFORMATION -- IDENTIFICATION AND SELECTION OF OUTLIERS IN A POPULATION -- EXAMPLES OF IMPORTANT GENETIC POLYMORPHISMS -- CONCLUSIONS AND FUTURE DIRECTIONS -- REFERENCES -- Chapter 14 -- Mechanisms and Genetics of Drug Transport -- INTRODUCTION -- MECHANISMS OF TRANSPORT ACROSS BIOLOGICAL MEMBRANES -- NOMENCLATURE, GENETIC CLASSIFICATION, AND FUNCTION OF SELECTED MEMBRANE TRANSPORTERS -- ROLE OF TRANSPORTERS IN PHARMACOKINETICS AND DRUG ACTION -- PHARMACOGENETICS AND PHARMACOGENOMICS OF MEMBRANE TRANSPORT. | |
| 505 | 8 | |a CONCLUSIONS AND FUTURE PERSPECTIVES -- REFERENCES -- Chapter 15 -- Drug Interactions -- INTRODUCTION -- MECHANISMS OF DRUG INTERACTIONS -- PREDICTING DRUG INTERACTIONS AND PRODUCT LABELING -- REFERENCES -- Chapter 16 -- Biochemical Mechanisms of Drug Toxicity -- INTRODUCTION -- DRUG-INDUCED LIVER TOXICITY -- IMMUNOLOGICALLY MEDIATED HEPATOTOXIC REACTIONS -- MECHANISMS OF OTHER DRUG TOXICITIES -- REFERENCES -- Chapter 17 -- Pharmacogenomic Mechanisms of Drug Toxicity -- INTRODUCTION -- ADRS WITH A PHARMACOGENOMIC BASIS -- GENETIC MECHANISMS FOR DRUG-INDUCED HYPERSENSITIVITY REACTIONS -- FDA LABELING OF DRUGS FOR PHARMACOGENOMIC INFORMATION -- THE ROLE OF SIMULATION IN ELUCIDATING PHARMACOGENOMIC ADR MECHANISMS -- THE ROLE OF CONSORTIA IN ELUCIDATING PHARMACOGENOMIC ADR MECHANISMS -- ACKNOWLEDGEMENT -- REFERENCES -- PART III -- ASSESSMENT OF DRUG EFFECTS -- Chapter 18 -- Physiological and Laboratory Markers of Drug Effect -- CONCEPTUAL FRAMEWORK -- IDENTIFICATION AND EVALUATION OF BIOMARKERS -- USES OF BIOMARKERS -- CASE STUDY: DEVELOPMENT AND USE OF SERUM CHOLESTEROL AS A BIOMARKER AND SURROGATE ENDPOINT -- FUTURE DEVELOPMENT OF BIOMARKERS -- REFERENCES -- Chapter 19 -- Imaging in Drug Development -- INTRODUCTION -- THE CASE FOR MOLECULAR IMAGING -- CHALLENGES TO USING IMAGING IN DRUG DEVELOPMENT -- MOLECULAR IMAGING TECHNOLOGIES -- IMAGING BIOMARKER EXAMPLES -- IMAGING BIOLOGY AND PREDICTING RESPONSE -- IMAGING THERAPEUTIC DRUG EFFECTS -- CONCLUSION -- REFERENCES -- Chapter 20 -- Dose-Effect and Concentration-Effect Analysis -- BACKGROUND -- DRUG-RECEPTOR INTERACTIONS -- THE GRADED DOSE-EFFECT RELATIONSHIP -- THE QUANTAL DOSE-EFFECT RELATIONSHIP -- PHARMACODYNAMIC MODELS -- CONCLUSION -- REFERENCES -- Chapter 21 -- Time Course of Drug Response -- PHARMACOKINETICS AND DELAYED PHARMACOLOGIC EFFECTS. | |
| 505 | 8 | |a PHYSIOKINETICS -- THE TIME COURSE OF EFFECTS DUE TO PHYSIOLOGICAL TURNOVER PROCESSES -- THERAPEUTIC RESPONSE, CUMULATIVE DRUG EFFECTS, AND SCHEDULE DEPENDENCE -- REFERENCES -- Chapter 22 -- Disease Progress Models -- CLINICAL PHARMACOLOGY AND DISEASE PROGRESS -- DISEASE PROGRESS MODELS -- DESIGN OF TRIALS TO STUDY DISEASE PROGRESS -- CONCLUSION -- REFERENCES -- PART IV -- OPTIMIZING AND EVALUATING PATIENT THERAPY -- Chapter 23 -- Pharmacological Differences between Men and Women -- INTRODUCTION -- PHARMACOKINETICS -- PHARMACODYNAMICS -- EFFECTS OF EXTRANEOUS FACTORS -- SUMMARY -- ACKNOWLEDGEMENT -- REFERENCES -- Chapter 24 -- Drug Therapy in Pregnant and Nursing Women -- PREGNANCY PHYSIOLOGY AND ITS EFFECTS ON PHARMACOKINETICS -- PHARMACOKINETIC STUDIES DURING PREGNANCY -- PLACENTAL TRANSFER OF DRUGS -- TERATOGENESIS -- DRUG THERAPY OF NURSING MOTHERS -- REFERENCES -- Chapter 25 -- Pediatric Clinical Pharmacology and Therapeutics -- INTRODUCTION -- ONTOGENY OF PHARMACOKINETICS IN CHILDREN -- DEVELOPMENTAL PHARMACODYNAMICS -- THERAPEUTIC CONSIDERATIONS -- APPLICATION OF PEDIATRIC PHARMACOLOGY TO CLINICAL STUDY DESIGN -- REFERENCES -- Chapter 26 -- Drug Therapy in the Elderly -- INTRODUCTION -- PATHOPHYSIOLOGY OF AGING -- AGE-RELATED CHANGES IN PHARMACOKINETICS -- AGE-RELATED CHANGES IN EFFECTOR SYSTEM FUNCTION -- DRUG GROUPS FOR WHICH AGE CONFERS INCREASED RISK FOR TOXICITY -- CONCLUSIONS -- REFERENCES -- Chapter 27 -- Clinical Analysis of Adverse Drug Reactions -- INTRODUCTION -- DEFINITIONS AND CLASSIFICATION -- ASSESSING ADR RISK -- MINIMIZING AND MANAGING ADRS -- REFERENCES -- Chapter 28 -- Quality Assessment of Drug Therapy -- INTRODUCTION -- ORGANIZATIONAL INFLUENCES ON MEDICATION-USE QUALITY -- SUMMARY -- REFERENCES -- PART V -- DRUG DISCOVERY AND DEVELOPMENT. | |
| 505 | 8 | |a Chapter 29 -- Portfolio and Project Planning and Management in the Drug Discovery, Evaluation, Development, and Regulatory R ... -- INTRODUCTION -- PORTFOLIO DESIGN, PLANNING, AND MANAGEMENT -- PROJECT PLANNING AND MANAGEMENT -- PROJECT PLANNING AND MANAGEMENT TOOLS -- PROJECT TEAM MANAGEMENT AND DECISION-MAKING -- REFERENCES -- Chapter 30 -- Drug Discovery -- INTRODUCTION -- DRUG DISCOVERY PHILOSOPHIES AND DEFINITION OF DRUG TARGETS -- GENERATING DIVERSITY -- DEFINITION OF LEAD STRUCTURES -- QUALIFYING LEADS FOR TRANSITION TO EARLY TRIALS -- ACKNOWLEDGEMENT -- REFERENCES -- Chapter 31 -- Non-Clinical Drug Development -- INTRODUCTION -- COMPONENTS OF NON-CLINICAL DRUG DEVELOPMENT -- TRANSLATIONAL RESEARCH IN ONCOLOGY DRUG DEVELOPMENT -- REFERENCES -- Chapter 32 -- Preclinical Prediction of Human Pharmacokinetics -- INTRODUCTION -- ALLOMETRY -- MICRODOSING -- PHYSIOLOGIC PHARMACOKINETICS -- REFERENCES -- Chapter 33 -- Phase I Clinical Studies -- INTRODUCTION -- DISEASE-SPECIFIC CONSIDERATIONS -- BEYOND TOXICITY -- REFERENCES -- Chapter 34 -- Pharmacokinetic and Pharmacodynamic Considerations in the Development of Biotechnology Products and Large Molecules -- INTRODUCTION -- MONOCLONAL ANTIBODIES -- ASSAY OF MACROMOLECULES -- INTERSPECIES SCALING OF MACROMOLECULES: PREDICTIONS IN HUMANS -- PHARMACOKINETIC CHARACTERISTICS OF MACROMOLECULES -- PHARMACODYNAMICS OF MACROMOLECULES -- REFERENCES -- Chapter 35 -- Design of Clinical Development Programs -- INTRODUCTION -- PRINCIPLES OF CLINICAL DEVELOPMENT -- LEGAL AND REGULATORY REQUIREMENTS -- EVIDENCE-BASED, GOAL-DIRECTED CLINICAL DEVELOPMENT -- SPECIFIC DESIGN ISSUES IN CLINICAL DEVELOPMENT PROGRAMS -- CONDUCT OF CLINICAL DEVELOPMENT -- SPECIAL TOPICS -- REFERENCES -- Chapter 36 -- The Role of the FDA in Guiding Drug Development -- WHY DOES THE FDA GET INVOLVED IN DRUG DEVELOPMENT? | |
| 504 | |a Includes bibliographical references. | ||
| 590 | |a ProQuest Ebook Central |b Ebook Central Academic Complete | ||
| 650 | 0 | |a Clinical pharmacology. | |
| 650 | 0 | |a Chemotherapy |x Nurses'' Instruction. | |
| 650 | 0 | |a Nursing. | |
| 650 | 0 | |a Pharmacology, Clinical |x Nurses'' Instruction. | |
| 650 | 2 | |a Pharmacology, Clinical | |
| 650 | 6 | |a Pharmacologie clinique. | |
| 650 | 7 | |a Clinical pharmacology |2 fast | |
| 650 | 7 | |a Nursing |2 fast | |
| 700 | 1 | |a Huang, Shiew-Mei. | |
| 700 | 1 | |a Lertora, Juan J. L. | |
| 700 | 1 | |a Markey, Sanford P. | |
| 758 | |i has work: |a Principles of clinical pharmacology (Text) |1 https://id.oclc.org/worldcat/entity/E39PCGBBkgDQgc7TFrrMmbJPXq |4 https://id.oclc.org/worldcat/ontology/hasWork | ||
| 776 | 0 | 8 | |i Print version: |z 9780123854711 |
| 856 | 4 | 0 | |u https://ebookcentral.uam.elogim.com/lib/uam-ebooks/detail.action?docID=998897 |z Texto completo |
| 938 | |a 123Library |b 123L |n 54461 | ||
| 938 | |a EBL - Ebook Library |b EBLB |n EBL998897 | ||
| 938 | |a YBP Library Services |b YANK |n 9592137 | ||
| 994 | |a 92 |b IZTAP | ||